Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07298395 · ClinicalTrials.gov registry record · Phase 2

Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis

A Phase 2 study of Atopic Dermatitis (AD), sponsored by Enveda Therapeutics.

Recruiting
Registry status
Phase 2
Development phase
64
Enrollment target
12
Study locations

NCT07298395 is a Phase 2 study of Atopic Dermatitis (AD) that is actively recruiting participants, run by Enveda Therapeutics. The registered enrollment target is 64 participants, below the 101-participant average among 7 other Atopic Dermatitis (AD) trials with a reported enrollment target (37% lower). The trial reports 12 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07298395, a Phase 2 study of Atopic Dermatitis (AD), is actively recruiting participants, sponsored by Enveda Therapeutics.

RECRUITING
Registry status
Phase 2
Development phase
64 participants
Enrollment target
12
Study locations

Study Summary

The goal of this clinical trial is to learn about the safety and effectiveness of ENV-294 in adults with moderate to severe atopic dermatitis. The main questions it will answer are: * Is there an impact on the severity and area of atopic dermatitis when participants take ENV-294 * What medical problems do participants have when taking ENV-294 Researchers will review the atopic dermatitis present at the beginning of the study against the atopic dermatitis present at the end of the study. Participants will: * Take drug ENV-294 or a placebo once every day for 12 weeks * Visit the clinic every 2 to 4 weeks for checkups and tests * Keep a diary of their symptoms and when they took their study drug ENV-294 * Return to the clinic for the final study visit at approximately week 16

Conditions Studied

Atopic Dermatitis (AD)

Interventions

  • DRUG Placebo
  • DRUG ENV-294

Study Locations (12)

Texas

  • Arlington Research Center - Arlington
  • Center for Clinical Studies - Houston
  • Texas Dermatology and Laser Specialists - San Antonio

California

  • Center for Dermatology Clinical Research - Fremont
  • TCR Medical Corporation - San Diego

Indiana

  • Southern Indiana Clinical Trials - New Albany
  • Options Research Group - West Lafayette

Alabama

  • Cahaba & Skin Health Center - Birmingham

Arkansas

  • Burke Pharmaceutical Research - Hot Springs

Michigan

  • Michigan Center for Skin Care Research - Clinton Township

Pennsylvania

  • Best Skin Research - Camp Hill

Virginia

  • Virginia Dermatology & Skin Cancer Center - Norfolk

Trial Details

FieldValue
Enrollment Target 64 participants
Start Date 2025-12-22
Est. Completion 2026-12
Phase Phase 2

Sponsor

Enveda Therapeutics

4 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07298395

The ClinicalTrials.gov registry entry for NCT07298395 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 101-participant average among 7 other Atopic Dermatitis (AD) trials with a reported enrollment target (37% lower). The listed sponsor is Enveda Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Atopic Dermatitis (AD) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT07298395 reports 12 study locations spanning 8 distinct geographic areas - top geographies include Texas, California, Indiana.

Frequently Asked Questions

What is clinical trial NCT07298395 about?

NCT07298395 is a clinical study titled "Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis". The goal of this clinical trial is to learn about the safety and effectiveness of ENV-294 in adults with moderate to severe atopic dermatitis. The main questions it will answer are: * Is there an impact on the severity and area of atopic dermatitis when participants take ENV-294 * What medical pro...

What is the current status of trial NCT07298395?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2025-12-22. Estimated completion is 2026-12.

What conditions does trial NCT07298395 study?

This clinical trial studies the following conditions: Atopic Dermatitis (AD).

What interventions are being tested in trial NCT07298395?

The interventions under investigation include: Placebo (DRUG), ENV-294 (DRUG).

Who is sponsoring clinical trial NCT07298395?

This trial is sponsored by Enveda Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07298395 being conducted?

This trial has 12 study locations across Alabama, Arkansas, California, Indiana, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Atopic Dermatitis (AD)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Atopic Dermatitis (AD)

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.